At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
Health Journal is a leader and influencer in health publishing in Virginia, USA an...
Health Journal is a leader and influencer in he...
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology compa...
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a...
Repligen Corporation is a global bioprocessing company that develops and commercia...
Repligen Corporation is a global bioprocessing ...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
Join the National Investor Network and get the latest information with your interests in mind.